2 news items
Cogent Biosciences Reports First Quarter 2024 Financial Results
COGT
7 May 24
costs and costs related to development of the research pipeline. R&D expenses include non-cash stock compensation expense of $4.4 million
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
COGT
26 Feb 24
the ongoing SUMMIT, PEAK and APEX registration-directed trials. R&D Expenses: Research and development expenses were $48.7
- Prev
- 1
- Next